Design, development, and in-vitro/in-vivo evaluation of docetaxel-loaded PEGylated solid lipid nanoparticles in prostate cancer therapy
Authors:
- 2 June 2023
- journal article
- research article
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 189, 15-27
Abstract
No abstract availableKeywords
Funding Information
- Chhatrapati Shahu Maharaj Research Training and Human Development Institute
This publication has 51 references indexed in Scilit:
- Docetaxel-Loaded Solid Lipid Nanoparticles: Preparation, Characterization, In Vitro, and In Vivo EvaluationsJournal of Pharmaceutical Sciences, 2013
- Thermotherapy using magnetic cationic liposomes powerfully suppresses prostate cancer bone metastasis in a novel rat modelThe Prostate, 2013
- PEGylated PRINT Nanoparticles: The Impact of PEG Density on Protein Binding, Macrophage Association, Biodistribution, and PharmacokineticsNano Letters, 2012
- Synergistic enhancement of cancer therapy using a combination of docetaxel and photothermal ablation induced by single-walled carbon nanotubesInternational Journal of Nanomedicine, 2011
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010
- Global Patterns of Cancer Incidence and Mortality Rates and TrendsCancer Epidemiology, Biomarkers & Prevention, 2010
- Stealth nanoparticles: High density but sheddable PEG is a key for tumor targetingJournal of Controlled Release, 2010
- Preparation and pharmacokinetics of docetaxel based on nanostructured lipid carriersJournal of Pharmacy and Pharmacology, 2009
- The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinomaBiomaterials, 2009
- Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere)International Journal of Cancer, 2003